Jie Wang

18.0k total citations · 4 hit papers
346 papers, 6.7k citations indexed

About

Jie Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jie Wang has authored 346 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 216 papers in Oncology, 163 papers in Pulmonary and Respiratory Medicine and 92 papers in Molecular Biology. Recurrent topics in Jie Wang's work include Lung Cancer Treatments and Mutations (115 papers), Cancer Immunotherapy and Biomarkers (89 papers) and Lung Cancer Research Studies (65 papers). Jie Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (115 papers), Cancer Immunotherapy and Biomarkers (89 papers) and Lung Cancer Research Studies (65 papers). Jie Wang collaborates with scholars based in China, United States and United Kingdom. Jie Wang's co-authors include Zhijie Wang, Hua Bai, Jianchun Duan, Jie He, Kailun Fei, Jianchun Duan, Ying Cheng, Hua Bai, Shun Lü and Jianying Zhou and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jie Wang

328 papers receiving 6.6k citations

Hit Papers

Nivolumab Versus Docetaxel in a Predominantly Chinese Pat... 2019 2026 2021 2023 2019 2019 2021 2021 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
    2019 265 citations Yi‐Long Wu, Ying Cheng et al. profile →
  2. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    2019 249 citations Jianchun Duan, Hua Bai et al. profile →
  3. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
    2021 246 citations Jie Wang, Yanping Hu et al. profile →
  4. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
    2021 160 citations Zhuoran Yao, Hua Bai et al. profile →

Peers

Jie Wang
Anish Thomas United States
Konstantinos N. Syrigos Greece
Xuefei Li China
Patrick Micke Sweden
Lin Li China
Akihiko Gemma Japan
Yi Hu China
Anil Vachani United States
Yoichi Nakanishi Japan
Chengping Hu China
Anish Thomas United States
Jie Wang
Citations per year, relative to Jie Wang Jie Wang (= 1×) peers Anish Thomas

Countries citing papers authored by Jie Wang

Since Specialization
Citations

This map shows the geographic impact of Jie Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jie Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jie Wang more than expected).

Fields of papers citing papers by Jie Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jie Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jie Wang. The network helps show where Jie Wang may publish in the future.

Co-authorship network of co-authors of Jie Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Jie Wang. A scholar is included among the top collaborators of Jie Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jie Wang. Jie Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Jie, Jie Zhou, Chunhui Jiang, et al.. (2024). Araloside A alleviates sepsis-induced acute lung injury via PHD2/HIF-1α in macrophages. Phytomedicine. 135. 156089–156089. 4 indexed citations
2.
Wang, Jie, Zhehai Wang, Yao Yu, et al.. (2024). Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8604–8604. 5 indexed citations
3.
Zhao, Jun, Jian Fang, Yan Yu, et al.. (2024). Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3008–3008. 12 indexed citations
4.
5.
Qu, Yan, Lihui Liu, Xun Zhang, et al.. (2023). Comparative proteomic profiling of plasma exosomes in lung cancer cases of liver and brain metastasis. Cell & Bioscience. 13(1). 180–180. 22 indexed citations
6.
7.
8.
9.
Bai, Hua, et al.. (2023). Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers. Frontiers in Oncology. 12. 1099304–1099304. 10 indexed citations
10.
Jin, Jing, Chengdi Wang, Pengwei Ren, et al.. (2023). Common nutritional/inflammatory indicators are not effective tools in predicting the overall survival of patients with small cell lung cancer undergoing first-line chemotherapy. Frontiers in Oncology. 13. 1211752–1211752. 3 indexed citations
11.
Li, Sini, Yan Qu, Lihui Liu, et al.. (2023). Tumour‐derived exosomes in liver metastasis: A Pandora's box. Cell Proliferation. 56(10). e13452–e13452. 15 indexed citations
12.
13.
Yang, Ting, Lei Yue, Hua Li, et al.. (2022). Comparative analysis of the biological characteristics of three CV‐A10 clones adaptively cultured on Vero cells. Journal of Medical Virology. 94(8). 3820–3828. 3 indexed citations
14.
Liu, Ying, Ying Cheng, Qiming Wang, et al.. (2021). Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. Thoracic Cancer. 12(22). 3039–3045. 8 indexed citations
15.
Cheng, Ying, Qiming Wang, Kai Li, et al.. (2021). Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. Cancer Medicine. 11(4). 1081–1087. 15 indexed citations
16.
Han, Jiefei, Jianchun Duan, Hua Bai, et al.. (2019). TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer. Cancer Immunology Research. 8(1). 146–154. 177 indexed citations
17.
Li, Ning, Yutao Liu, Jianchun Duan, et al.. (2019). Prognostic significance of molecular characteristics of cerebrospinal fluid for non‐small cell lung cancer patients with leptomeningeal metastasis. Thoracic Cancer. 10(8). 1673–1682. 10 indexed citations
18.
Yu, Jiangyong, Shuhang Wang, Wei Zhao, et al.. (2018). Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer. Clinical Cancer Research. 24(9). 2148–2158. 47 indexed citations
19.
Wang, Yuyan, Li Liu, Jia Zhong, et al.. (2015). [Prognostic factors and response of chemotherapy including amrubicin in small cell lung cancer patients].. PubMed. 38(4). 261–6. 1 indexed citations
20.
Zhang, Xu‐Chao, Li Zhang, Changli Wang, et al.. (2013). [Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].. PubMed. 42(6). 402–6. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anish Thomas Breakdown of academic impact, for papers by Konstantinos N. Syrigos Breakdown of academic impact, for papers by Xuefei Li Breakdown of academic impact, for papers by Patrick Micke Breakdown of academic impact, for papers by Lin Li Breakdown of academic impact, for papers by Akihiko Gemma Breakdown of academic impact, for papers by Yi Hu Breakdown of academic impact, for papers by Anil Vachani Breakdown of academic impact, for papers by Yoichi Nakanishi Breakdown of academic impact, for papers by Chengping Hu
Rankless by CCL
2026